Figure 1From: Disorder-specific effects of polymorphisms at opposing ends of the Insulin Degrading Enzymegene Amyloid β 42 (Aβ 42 ) plasma levels [pg/ml]. A) in insulin degrading enzyme IDE2 SNP (rs4646953) genotypes and B) in IDE2 genotypes stratified by Alzheimer's disease (AD) status (AD no/yes) at baseline, 1st and 2nd follow-ups.Back to article page